TP53 and colorectal carcinoma: In other words, targeted therapy may benefit the OS of partial CRC patients with specific TP53 mutations (GOF or known LOF mutations), whereas probably has no significant impact on the OS of CRC patients with other TP53 mutations (non‐GOF or likely LOF mutations).